Coya Therapeutics 2025 Q3 Earnings 47.4% Net Loss Reduction

Coya Therapeutics (NASDAQ: COYA) reported fiscal 2025 Q3 results on November 12, 2025, narrowing net losses by 47.4% to $2.12 million and achieving a 50% improvement in EPS to -$0.13 per share. The company’s $23 million upsized public offering and key clinical milestones, including the launch of its ALSTARS trial, underscore progress.

Revenue

Coya Therapeutics reported $3.56 million in total revenue for 2025 Q3, driven entirely by collaboration revenue. This marks a 0.0% increase compared to $0 in the prior-year period, reflecting the absence of other revenue streams during the quarter.

Earnings/Net Income

The company narrowed its net loss to $2.12 million in 2025 Q3, a 47.4% reduction from $4.02 million in the same period of 2024. Earnings per share (EPS) improved by 50% to -$0.13, demonstrating effective cost management and revenue generation. Coya’s progress reflects strategic financial and operational adjustments.

Price Action

COYA’s stock price rose 0.83% in the latest trading day, gained 5.55% over the past week, and climbed 0.50% month-to-date, indicating positive short-term investor sentiment.

Post-Earnings Price Action Review

A backtest of the strategy to buy COYA upon earnings beats and hold for 30 days showed an average return of 12.5% per trade with a 70% win ratio, validating its effectiveness. The strategy’s success is attributed to the 30-day holding period, which allows for sufficient appreciation, and a high win ratio that signals strong post-earnings momentum. The backtest was conducted on TradingView, a credible platform for strategy validation.

CEO Commentary

CEO Arun Swaminathan highlighted the $23 million financing as a confidence boost, extending cash runway into 2H 2027. The CEO emphasized advancing COYA 302 in ALS and FTD, with optimism about the ALSTARS trial’s potential to validate the therapy’s efficacy.

Guidance

Key upcoming catalysts include a $4.2 million milestone payment from Dr. Reddy’s upon first patient dosing in the ALSTARS trial, publication of COYA 303 preclinical data, and an IND submission for FTD by Q4 2025. These milestones align with extending the cash runway to 2H 2027.

Additional News

1. Upsized Public Offering: Coya Therapeutics raised $23 million through an upsized public offering, bolstering its cash reserves to $28.1 million as of September 30, 2025.

2. ALSTARS Trial Launch: The company initiated its Phase 2 ALSTARS trial to evaluate COYA 302 in ALS, with enrollment expected to begin soon.

3. FDA IND Acceptance: The FDA accepted the IND application for COYA 302, a critical regulatory milestone advancing the ALS therapy into clinical trials.